论文部分内容阅读
目的:探讨伊立替康、拓扑替康对老年小细胞肺癌进行临床单药治疗的疗效以及不良反应差异性比较。方法:选取2011年2月至2013年2月期间收治的64例经临床病理进行确诊的老年小细胞肺癌患者作为本次的研究对象,针对患者意愿且按照入院就诊顺序随机均分为CPT组(选用伊立替康进行治疗)与TPT组(选用拓扑替康进行治疗)各32例,对两组患者的临床疗效以及不良反应进行对照比较。结果:两组患者的临床疗效比较差异无统计学意义(P>0.05),TPT组患者的白细胞减少量与CPT组相比较高,差异具有统计学意义(P<0.05)。不良反应方面,CPT的患者延迟性腹泻症状发生率高于TPT组,差异具有统计学意义(P<0.05),其他不良反应两组比较差异无统计学意义(P>0.05)。结论:两组患者疗效近似,但是用药后反应差异较为明显,可按照患者的临床症状进行对症用药。
Objective: To investigate the efficacy of irinotecan and topotecan in the treatment of elderly patients with small cell lung cancer and their differences in adverse reactions. Methods: Sixty-four patients with senile small cell lung cancer confirmed by clinicopathology from February 2011 to February 2013 were selected as the study subjects. The patients were randomly divided into CPT group The use of irinotecan for treatment) and TPT group (treatment with topotecan) in 32 cases, the clinical efficacy of the two groups of patients and adverse reactions were compared. Results: There was no significant difference in clinical efficacy between the two groups (P> 0.05). The leukopenia in TPT group was higher than that in CPT group (P <0.05). Adverse reactions, the incidence of delayed diarrhea in patients with CPT was higher than the TPT group, the difference was statistically significant (P <0.05), other adverse reactions in both groups showed no significant difference (P> 0.05). Conclusion: The curative effect of two groups of patients is similar, but the difference of response after treatment is obvious. According to the clinical symptoms of patients, symptomatic treatment can be carried out.